Champions Oncology Inc.
| NASDAQ: CSBR | Healthcare / Biotechnology / USA |
| 5.30 | +0.1500 | +2.91% | Vol 16.39K | 1Y Perf -24.98% |
| Dec 1st, 2023 16:00 DELAYED |
| BID | 4.85 | ASK | 5.45 | ||
| Open | 5.33 | Previous Close | 5.15 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 14.50 | Analyst Rating | Moderate Buy 2.00 | |
| Potential % | 173.59 | Finscreener Ranking | ★ 42.13 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | + 34.44 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★ 50.94 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 43.42 | Earnings Rating | Neutral | |
| Market Cap | 71.44M | Earnings Date | 12th Dec 2023 | |
| Alpha | -0.01 | Standard Deviation | 0.16 | |
| Beta | 0.83 |
Today's Price Range 5.015.45 | 52W Range 3.757.32 | 5 Year PE Ratio Range -37.101.04K |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.36% | ||
| 1 Month | -6.53% | ||
| 3 Months | -18.77% | ||
| 6 Months | 3.00% | ||
| 1 Year | -24.98% | ||
| 3 Years | -54.18% | ||
| 5 Years | -59.35% | ||
| 10 Years | -57.08% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -14.65 | |||
ROE last 12 Months | 1.34 | |||
ROA (5Y Avg) | -1.18 | |||
ROA last 12 Months | 0.35 | |||
ROC (5Y Avg) | -124.35 | |||
ROC last 12 Months | 0.61 | |||
Return on invested Capital Q | -0.09 | |||
Return on invested Capital Y | 3.08 | |||
Assets Turnover | 1.80 | |||
Receivables Turnover | 7.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 486.60 | ||||
| 6.34 | ||||
| 1.09 | ||||
| 7.30 | ||||
| 9.90 | ||||
| 0.59 | ||||
| 6.58 | ||||
| 0.68 | ||||
| 56.31M | ||||
| Forward PE | 109.99 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.10 | ||||
| 1.10 | ||||
| 0.46 | ||||
| 0.98 | ||||
| - | ||||
| Leverage Ratio | 3.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 47.20 | ||||
| 0.40 | ||||
| 4.20 | ||||
| -2.00 | ||||
| 0.18 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 54.10M | ||||
| 3.99 | ||||
| 19.42 | ||||
| 20.97 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -0.19 | - |
| Q04 2023 | - | -0.19 | - |
| Q03 2023 | -0.06 | -0.18 | -200.00 |
| Q02 2023 | 0.01 | 0.00 | -100.00 |
| Q01 2023 | 0.01 | -0.02 | -300.00 |
| Q04 2022 | 0.02 | -0.03 | -250.00 |
| Q03 2022 | 0.03 | 0.05 | 66.67 |
| Q02 2022 | 0.00 | 0.02 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 10/2023 QR | -0.17 | -270.00 | Negative |
| 1/2024 QR | -0.04 | - | - |
| 4/2024 FY | -0.40 | - | - |
| 4/2025 FY | 0.05 | - | - |
| Next Report Date | 12th Dec 2023 |
| Estimated EPS Next Report | -0.17 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 16.39K |
| Shares Outstanding | 13.48K |
| Shares Float | 4.75M |
| Trades Count | 350 |
| Dollar Volume | 86.07K |
| Avg. Volume | 6.83K |
| Avg. Weekly Volume | 6.44K |
| Avg. Monthly Volume | 5.60K |
| Avg. Quarterly Volume | 8.46K |
Champions Oncology Inc. (NASDAQ: CSBR) stock closed at 5.15 per share at the end of the most recent trading day (a -3.01% change compared to the prior day closing price) with a volume of 6.27K shares and market capitalization of 71.44M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 143 people. Champions Oncology Inc. CEO is Ronnie Morris.
The one-year performance of Champions Oncology Inc. stock is -24.98%, while year-to-date (YTD) performance is 14.19%. CSBR stock has a five-year performance of -59.35%. Its 52-week range is between 3.75 and 7.32, which gives CSBR stock a 52-week price range ratio of 43.42%
Champions Oncology Inc. currently has a PE ratio of 486.60, a price-to-book (PB) ratio of 6.34, a price-to-sale (PS) ratio of 1.09, a price to cashflow ratio of 7.30, a PEG ratio of -, a ROA of 0.35%, a ROC of 0.61% and a ROE of 1.34%. The company’s profit margin is 0.18%, its EBITDA margin is 4.20%, and its revenue ttm is $54.10 Million , which makes it $3.99 revenue per share.
Of the last four earnings reports from Champions Oncology Inc., there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. Champions Oncology Inc.’s next earnings report date is 12th Dec 2023.
The consensus rating of Wall Street analysts for Champions Oncology Inc. is Moderate Buy (2), with a target price of $14.5, which is +173.59% compared to the current price. The earnings rating for Champions Oncology Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Champions Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Champions Oncology Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.66, ATR14 : 0.29, CCI20 : -184.04, Chaikin Money Flow : -0.17, MACD : -0.18, Money Flow Index : 34.81, ROC : -6.19, RSI : 36.86, STOCH (14,3) : 7.69, STOCH RSI : 0.14, UO : 43.12, Williams %R : -92.31), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Champions Oncology Inc. in the last 12-months were: Mendelson Daniel (Buy at a value of $299 626), Morris Ronnie (Buy at a value of $50 023), Ronnie Morris (Buy at a value of $49 969)
Champions Oncology Inc.
Champions Oncology Inc is a US-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
CEO: Ronnie Morris
Telephone: +1 201 808-8400
Address: One University Plaza, Hackensack 07601, NJ, US
Number of employees: 143
TipRanks News for CSBR
Mon, 16 Oct 2023 13:10 GMT Analysts Offer Insights on Healthcare Companies: Champions Oncology (CSBR), Walgreens Boots Alliance (WBA) and Harrow Health (HROW)
- TipRanks. All rights reserved.
